UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,812	06/22/2006	Richard Cooper	51687-0261 (331126)	4921
	23370 7590 08/05/2010 JOHN S. PRATT, ESQ		EXAMINER	
KILPATRICK STOCKTON, LLP			SAJJADI, FEREYDOUN GHOTB	
SUITE 2800	1100 PEACHTREE STREET SUITE 2800 ATLANTA, GA 30309		ART UNIT	PAPER NUMBER
ATLANTA, GA			1633	
			MAIL DATE	DELIVERY MODE
			08/05/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
Office Action Summary	10/583,812	COOPER ET AL.		
Onice Action Summary	Examiner	Art Unit		
TI MAIL INO DATE (4)	FEREYDOUN G. SAJJADI	1633		
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the o	correspondence address		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tirwill apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).		
Status				
Responsive to communication(s) filed on 22 J     This action is <b>FINAL</b> . 2b) ☑ This     Since this application is in condition for allowed closed in accordance with the practice under the second seco	s action is non-final. nnce except for formal matters, pro			
Disposition of Claims				
4)  Claim(s) 1-8,10-22,24 and 25 is/are pending i 4a) Of the above claim(s) is/are withdra 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) 1-8,10-22,24 and 25 are subject to re	own from consideration.	ent.		
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>				
Attachment(s) 1) ☑ Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	r (PTO-413)		
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate		

## DETAILED ACTION

Pursuant to the preliminary amendment dated June 22, 2006, claims 1-8, 10-22, 24 and 25 are pending in the application.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

1. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-7, 14 and 22, drawn to a transposon-based vector comprising a transposase gene operably linked to a first promoter, and one or more genes of interest operably linked to one or more additional promoters, flanked by transposon insertion sequences.

Group II, claim(s) 8, 10-12 and 21, drawn to an animal, mammal, bird or a human comprising an isolated polynucleotide sequence comprising one or more genes of interest operably linked to one or more additional promoters, flanked by transposon insertion sequences and a poly-A nucleotide sequence; and an egg, milk or a cell of said mammal, bird or a human.

Group III, claim(s) 13, 15-20, 24 and 25, drawn to a method for providing gene therapy, comprising administering to an animal a transposon-based vector comprising a transposase gene operably linked to a first promoter, and one or more genes of interest operably linked to one or more additional promoters, flanked by transposon insertion sequences.

## REQUIREMENT FOR UNITY OF INVENTION

As provided in 37 CFR 1.475(a), a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in a national stage application, the requirement of unity of invention shall be fulfilled only when there is a technical

Art Unit: 1633

relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Inventions I and III are related as product and method of using said product. According to PCT Rule 13.2, unity of invention exists only when a shared same or corresponding special technical feature is a contribution over the prior art. The technical feature, which is shared by Groups I-III, is a transposon-based vector comprising a transposase gene operably linked to a first promoter, and one or more genes of interest operably linked to one or more additional promoters, flanked by transposon insertion sequences. Groups I-III do not share a special technical feature over the art because such was previously known in the prior art, as evidenced by Cooper (U.S. Patent No.: 5,719,055; 17 February 1998), teaching a vector for inserting an exogenous gene into a chromosome of a eukaryotic cell, comprising: a) a gene encoding a bacterial transposase; b) two transposon insertion sequences recognized by the transposase c) an exogenous gene, wherein said exogenous gene is between the two transposon insertion sequences; and (d) a promoter that is operably linked to said transposase gene; wherein one of said insertion sequences is located between said transposase gene and said exogenous gene; and wherein the transposase expressed by said transposase gene will excise from said vector a fragment comprising the two transposon insertion sequences and the exogenous gene between the two transposon insertion sequences, and will insert the excised fragment into a chromosome of a eukaryotic cell (claim 1, columns 27-28).

Thus, it follows from the preceding analysis that the claimed inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1, because under PCT Rule 13.2, they lack the same or corresponding technical feature.

Art Unit: 1633

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Genes or interest encoding a protein or comprising a nucleic acid which inhibits transcription, as recited in claims 4, 5, 7, 15, 17 and 25 for example.

Various animals, that include a mammal, bird or human, as recited in claims 8, 12, 13 and 22.

Applicant is required, in reply to this action, to elect a single specific species for each of the categories above, to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner: Claims 1, 8, 13, 14, 21, 22 and claims dependent therefrom.

The following claim(s) are generic: 1-8, 10-22, 24 and 25.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

As the technical features for the various distinct gene sequences and animals linking the members do not constitute a special technical feature as defined by PCT Rule 13.2, particularly since each of the species does not share a substantially common structural feature, the requirement for unity of invention is not fulfilled. The special technical feature of each species is the particular relevant identifying characteristics of that species, such as the particular composition and chemical make up of the gene sequences and animals. These features being

Art Unit: 1633

unique to each species and not shared by any other cannot be a unifying feature. The species therefore lack unity of invention *a priori*.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be

Application/Control Number: 10/583,812 Page 6

Art Unit: 1633

amended during prosecution to require the limitations of the product claims. **Failure to do so** may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to FEREYDOUN G. SAJJADI whose telephone number is (571)272-3311. The examiner can normally be reached on 6:30 AM-3:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Fereydoun G Sajjadi/ Primary Examiner, Art Unit 1633